FDA approves Darzalex (Daratumumab) combination drug to treat multiple myeloma patients

multiple myeloma is a malignant blood cancer caused by plasma cell cancer in the bone marrowtoday, johnson-owned janson(http:// announcedthat the U.SFDA(http://approved the company's joint development of Daratumab with Genmab, in conjunction with lenalidomide and dexamethasone, to treat patients with primary myeloid myeloma (ASCT)this combination of therapy, which reduces the risk of disease progression or death by 44 percent compared to the standard therapy (Rd) made up of amine and dexamethasoneAbout Darzalex
Darzalex can specifically identify CD38 highly expressed in malignant plasma cells of multiple myeloma in a high affinity, and then induce tumor cell death through a variety of immunomediated mechanismsSince its inception in 2015, Darzalex has received FDA approval to extend the scope of treatment for patients with multiple myelomaThis approved combination therapy is the second FDA-approved first-line multiple myeloma therapy with Darzalex, providing patients with more treatment optionsThe approval for the MAIAis based on an open label called MAIA, a randomized 3 clinicaltrial(http:// A total of 737 first-time patients received Darzalex-Rd or Rd treatment results show that adding Darzalex to the Rd treatment program can further improve the patient's response The Darzalex combination reduced the risk of disease progression or death by 44% compared to Rd Moreover, the patient's full remission rate (48 per cent vs 25 per cent), very good partial remission rate (79 per cent vs 53 per cent) and total remission rate (93 per cent vs 81 per cent) were significantly improved The proportion of patients with a negative microresidual lesions (MRD) in the Darzalex combination therapy group was three times higher than in the control group (24 percent vs 7 percent)